The search for and potential therapeutic applications of chemical inhibitors of cyclin-dependent kinases

被引:13
作者
Borgne, A [1 ]
Meijer, L [1 ]
机构
[1] CNRS, Biol Stn, F-29682 Roscoff, France
来源
M S-MEDECINE SCIENCES | 1999年 / 15卷 / 04期
关键词
D O I
10.4267/10608/1375
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Cyclin-dependent kinases (CDK1, 2, 3, 4, 6, 7) trigger and coordinate the cell division cycle phases. They also play a role in neuronal cells (CDK5) and in the control of transcription (CDK 7, 8, 9). Intensive screening has lead in a few years to the identification of a series of chemical inhibitors of CDKs. Some of these compounds display remarkable selectivities and efficiencies (IC50 < 25 nhl). Many have been co-cristallised with CDK2 and their atomic interactions with the kinase have been analysed in detail: all are located in the ATP-binding pocket of the enzyme. These inhibitors are antimitotic, they arrest cells in GI and, at higher doses, in G2/M. Furthermore they facilitate or even trigger apoptosis in proliferating cells. In contrast, they protect neuronal cells from apoptosis. The potential use of these inhibitors is being extensively evaluated in cancer chemotherapy (clinical trials, phase I and II). Possible clinical applications are being investigated in other fields: cardiovascular (restenosis, tumoral angiogenesis, atherosclerosis), dermatology (psoriasis), nephrology (glomerulonephritis), parasitology (unicellular parasites such as Plasmodium, trypanosomes, toxoplasm, etc.), neurology (Alzheimer's disease), viral infections (cytomegalovirus, HIV, herpes). We anticipate the discovery of novel selective and powerful inhibitors in the near future and hope for their efficient applications in various human pathologies.
引用
收藏
页码:496 / 503
页数:8
相关论文
共 45 条
  • [1] CELLULAR EFFECTS OF OLOMOUCINE, AN INHIBITOR OF CYCLIN-DEPENDENT KINASES
    ABRAHAM, RT
    ACQUARONE, M
    ANDERSEN, A
    ASENSI, A
    BELLE, R
    BERGER, F
    BERGOUNIOUX, C
    BRUNN, G
    BUQUETFAGOT, C
    FAGOT, D
    GLAB, N
    GOUDEAU, H
    GOUDEAU, M
    GUERRIER, P
    HOUGHTON, P
    HENDRIKS, H
    KLOAREG, B
    LIPPAI, M
    MARIE, D
    MARO, B
    MEIJER, L
    MESTER, J
    MULNERLORILLON, O
    POULET, SA
    SCHIERENBERG, E
    SCHUTTE, B
    VAULOT, D
    VERLHAC, MH
    [J]. BIOLOGY OF THE CELL, 1995, 83 (2-3) : 105 - 120
  • [2] Arguello F, 1998, BLOOD, V91, P2482
  • [3] Bible KC, 1996, CANCER RES, V56, P4856
  • [4] Inhibition of cellular Cdk2 activity blocks human cytomegalovirus replication
    Bresnahan, WA
    Boldogh, I
    Chi, P
    Thompson, EA
    Albrecht, T
    [J]. VIROLOGY, 1997, 231 (02) : 239 - 247
  • [5] CVT-313, a specific and potent inhibitor of CDK2 that prevents neointimal proliferation
    Brooks, EE
    Gray, NS
    Joly, A
    Kerwar, SS
    Lum, R
    Mackman, RL
    Norman, TC
    Rosete, J
    Rowe, M
    Schow, SR
    Schultz, PG
    Wang, XB
    Wick, MM
    Shiffman, D
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (46) : 29207 - 29211
  • [6] BRUSSELBACH S, 1999, IN PRESS INT J CANC
  • [7] Carlson BA, 1996, CANCER RES, V56, P2973
  • [8] NEW CELL-CYCLE REGULATORS - THE CDK-CYCLINS MODULATORY PROTEINS
    DARBON, JM
    FESQUET, D
    CAVADORE, JC
    [J]. M S-MEDECINE SCIENCES, 1995, 11 (03): : 349 - 356
  • [9] Inhibition of cyclin-dependent kinases by purine analogues - Crystal structure of human cdk2 complexed with roscovitine
    DeAzevedo, WF
    Leclerc, S
    Meijer, L
    Havlicek, L
    Strnad, M
    Kim, SH
    [J]. EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 243 (1-2): : 518 - 526
  • [10] Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase
    deAzevedo, WF
    MuellerDieckmann, HJ
    SchulzeGahmen, U
    Worland, PJ
    Sausville, E
    Kim, SH
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (07) : 2735 - 2740